Incyte Stock: Multiple Drug Launches Bode for Future Growth (NASDAQ: INCY )
Brendan, born in Pennsylvania: -Completed a Ph.D. Area of Organic Synthesis, Stanford University (2009). – Worked for a large pharmaceutical company (Merck, 2009-2013). First employee and co-founder out of Caltech received significant investment (to the tune of 8 figures).
Analysts revealed: I/we hold a beneficial long position in INCY stock through equity, options or other derivatives. This article was written by myself and expresses my own opinions. I received no compensation (other than from Seeking Alpha). I have no business relationships with any of the companies whose stock is mentioned in this article.
All investment opportunities carry inherent risks, including potential loss of principal. Before making any investment, please carefully consider your investment objectives, level of experience and risk appetite. The above discussion is a framework for investors (long and short) to understand the factors that affect the price of the underlying security. This is not a prediction and should not be considered investment advice.
Seeking Alpha Disclosure: Past performance is no guarantee of future results. No advice or recommendation is given as to whether any investment is suitable for a particular investor. Any views or opinions stated above may not reflect the views of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or U.S. investment adviser or investment bank. Our analysts are third-party authors, including professional and individual investors, who may not be licensed or certified by any agency or regulatory body.
